Back to search
FDAFDA · Food and drugs·Recall number D-0051-2027

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10

Published October 28, 2026 · Recall initiated: September 29, 2026

Summary

FDA records drug Class II recall D-0051-2027, published October 28, 2026 and initiated September 29, 2026. Recalling firm: Pfizer; Status: Ongoing; Reported quantity: 134 1000-count bottles; Lot: Lot # 24W07, Exp: 11/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOXYL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOXYL
Manufacturer
Pfizer
Distributor
US Nationwide and Puerto Rico
UPC
0360793858012
Lot
Lot # 24W07, Exp: 11/30/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10 recalled?

Yes. FDA published recall D-0051-2027 on October 28, 2026. Reported hazard: Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOXYL. UPC: 0360793858012.